Immunotherapy plus chemo for locally advanced head and neck cancer
Part of Cancer clinical trials.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old.
- Your head and neck cancer is confirmed as squamous cell carcinoma by biopsy or cell testing.
- You have a tumor that is large enough to measure on scans and you’re stage III–IVb (P16 negative) or stage II–III (P16 positive).
- You have not had any cancer treatment yet (no prior radiation, chemotherapy, surgery, or immunotherapy), especially not in the last 6 months.
- You’re well enough for treatment based on blood tests (like white blood cells, hemoglobin, and platelets) and key liver/kidney clotting labs within set limits.
- You can provide tumor tissue for gene-expression testing and can follow study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This study tests a new treatment approach for head and neck cancer that can't be removed with surgery. You would get a combination of an immunotherapy drug (which helps your immune system fight cancer) and chemotherapy first, followed by the standard chemoradiation therapy.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Head and Neck Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.